Earnings and Growth Analysis : XTL Biopharmaceuticals (NASDAQ:XTLB)

0
409

Earnings results for XTL Biopharmaceuticals (NASDAQ:XTLB)

XTL Biopharmaceuticals Ltd. is estimated to report earnings on 12/02/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.24.

XTL Biopharmaceuticals last posted its quarterly earnings results on August 24th, 2020. The biopharmaceutical company reported ($0.08) EPS for the quarter. XTL Biopharmaceuticals has generated $0.00 earnings per share over the last year. XTL Biopharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, December 2nd, 2020 based off prior year’s report dates.

Analyst Opinion on XTL Biopharmaceuticals (NASDAQ:XTLB)

Dividend Strength: XTL Biopharmaceuticals (NASDAQ:XTLB)

XTL Biopharmaceuticals does not currently pay a dividend. XTL Biopharmaceuticals does not have a long track record of dividend growth.

Insiders buying/selling: XTL Biopharmaceuticals (NASDAQ:XTLB)

In the past three months, XTL Biopharmaceuticals insiders have not sold or bought any company stock. Only 8.55% of the stock of XTL Biopharmaceuticals is held by institutions.

Earnings and Valuation of XTL Biopharmaceuticals (NASDAQ:XTLB

The P/E ratio of XTL Biopharmaceuticals is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of XTL Biopharmaceuticals is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. XTL Biopharmaceuticals has a P/B Ratio of 1.78. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here